| Assessment Status | Full HTA submission received from Applicant |
| HTA ID | 23005 |
| Drug | Burosumab |
| Brand | Crysvita® |
| Indication | Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients. |
| Assessment Process | |
| Rapid review commissioned | 03/02/2023 |
| Rapid review completed | 14/03/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of burosumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/03/2023 |
| Pre-submission consultation with Applicant | 13/06/2023 |
| Full submission received from Applicant | 19/09/2023 |
